Chinese Hepatolgy ›› 2026, Vol. 31 ›› Issue (6): 778-786.
Previous Articles Next Articles
Received:2026-05-30
Online:2026-06-30
Published:2026-07-29
| [1] Younossi Z M, Golabi P, Paik J M, et al. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review[J]. Hepatology,2023, 77(4): 1335-1347. [2] Rinella M E, Lazarus J V, Ratziu V, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature[J]. J Hepatol,2023, 79(6): 1542-1556. [3] European Association for the Study of the Liver, European Association for the Study of Diabetes, European Association for the Study of Obesity. EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)[J]. J Hepatol,2024, 81(3): 492-542. [4] Mantovani A, Csermely A, Petracca G, et al. Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis[J]. Lancet Gastroenterol Hepatol,2021, 6(11): 903-913. [5] Dulai P S, Singh S, Patel J, et al. Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis[J]. Hepatology,2017, 65(5): 1557-1565. [6] Ekstedt M, Hagstrom H, Nasr P, et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up[J]. Hepatology,2015, 61(5): 1547-1554. [7] Le M H, Yeo Y H, Li X, et al. 2019 Global NAFLD prevalence: a systematic review and meta-analysis[J]. Clin Gastroenterol Hepatol,2022, 20(12): 2809-2817.e28. [8] Li J, Zou B, Yeo Y H, et al. Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999-2019: a systematic review and meta-analysis[J]. Lancet Gastroenterol Hepatol,2019, 4(5): 389-398. [9] Wu Y, Zheng Q, Zou B, et al. The epidemiology of NAFLD in Mainland China with analysis by adjusted gross regional domestic product: a meta-analysis[J]. Hepatol Int,2020, 14(2): 259-269. [10] Zhu Y, Liu C, Xu X, et al. Association of diabetes mellitus with all-cause and cause-specific mortality among patients with metabolic-dysfunction-associated fatty liver disease: a longitudinal cohort study[J]. J Pers Med,2023, 13(3): 554. [11] Quek J, Chan K E, Wong Z Y, et al. Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: a systematic review and meta-analysis[J]. Lancet Gastroenterol Hepatol,2023, 8(1): 20-30. [12] En Li Cho E, Ang C Z, Quek J, et al. Global prevalence of non-alcoholic fatty liver disease in type 2 diabetes mellitus: an updated systematic review and meta-analysis[J]. Gut,2023, 72(11): 2138-2148. [13] Byrne C D, Targher G. NAFLD: a multisystem disease[J]. J Hepatol,2015, 62(1 Suppl): S47-S64. [14] Thomas J A, Kendall B J, Dalais C, et al. Hepatocellular and extrahepatic cancers in non-alcoholic fatty liver disease: a systematic review and meta-analysis[J]. Eur J Cancer,2022, 173:250-262. [15] Chen Q, Zhu Y, Gao J, et al. Cardiovascular-kidney-metabolic (CKM) syndrome is associated with increased mortality in individuals with metabolic dysfunction-associated steatotic liver disease (MASLD)[J]. Commun Med (Lond),2025, 5(1): 492. [16] Cheng P N, Chen W J, Hou C J, et al. Taiwan association for the study of the liver-Taiwan society of cardiology Taiwan position statement for the management of metabolic dysfunction-associated fatty liver disease and cardiovascular diseases[J]. Clin Mol Hepatol,2024, 30(1): 16-36. [17] Ma X, Zhu Y, Yeo Y H, et al. The impact of an increased fibrosis-4 index and the severity of hepatic steatosis on mortality in individuals living with diabetes[J]. Hepatol Int,2024, 18(3): 952-963. [18] Qi X, Li J, Caussy C, et al. Epidemiology, screening, and co-management of type 2 diabetes mellitus and metabolic dysfunction-associated steatotic liver disease[J]. Hepatology,2026, 83(3): 661-678. [19] Rowe I A. Optimal strategies to prevent disease progression and clinical events in MASLD[J]. J Hepatol,2026, 84(2): 245-247. [20] Zhou X D, Lian L Y, Chen Q F, et al. Effect of hypertension on long-term adverse clinical outcomes and liver fibrosis progression in MASLD[J]. J Hepatol,2026, 84(2): 254-265. [21] Liu J, Lv H, Wang J, et al. Blood pressure stratification for predicting liver fibrosis risk in metabolic dysfunction associated fatty liver disease[J]. Ann Hepatol,2023, 28(2): 100892. [22] Anstee Q M, Targher G, Day C P. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis[J]. Nat Rev Gastroenterol Hepatol,2013, 10(6): 330-344. [23] Targher G, Byrne C D, Tilg H. NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications[J]. Gut,2020, 69(9): 1691-1705. [24] Tilg H, Moschen A R. Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis[J]. Hepatology,2010, 52(5): 1836-1846. [25] Romeo S, Kozlitina J, Xing C, et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease[J]. Nat Genet,2008, 40(12): 1461-1465. [26] Eslam M, Valenti L, Romeo S. Genetics and epigenetics of NAFLD and NASH: clinical impact[J]. J Hepatol,2018, 68(2): 268-279. [27] Boursier J, Mueller O, Barret M, et al. The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota[J]. Hepatology,2016, 63(3): 764-775. [28] Le Roy T, Llopis M, Lepage P, et al. Intestinal microbiota determines development of non-alcoholic fatty liver disease in mice[J]. Gut,2013, 62(12): 1787-1794. [29] Chen H, Liu L, Wang Y, et al. Burden of cardiovascular disease attributable to metabolic risks in 204 countries and territories from 1990 to 2021[J]. Eur Heart J Qual Care Clin Outcomes,2025, 11(4): 467-476. [30] Wu S, Xu W, Guan C, et al. Global burden of cardiovascular disease attributable to metabolic risk factors, 1990-2019: an analysis of observational data from a 2019 Global Burden of Disease study[J]. BMJ Open,2023, 13(5): e069397. [31] Mantovani A, Petracca G, Csermely A, et al. Non-alcoholic fatty liver disease and risk of new-onset heart failure: an updated meta-analysis of about 11 million individuals[J]. Gut,2023, 72(2): 372-380. [32] Park H, Cheuk-Fung Yip T, Yoon E L, et al. Impact of cardiometabolic risk factors on hepatic fibrosis and clinical outcomes in MASLD: a population-based multi-cohort study[J]. JHEP Rep,2025, 7(6): 101388. [33] Kim K S, Hong S, Han K, et al. Association of non-alcoholic fatty liver disease with cardiovascular disease and all cause death in patients with type 2 diabetes mellitus: nationwide population based study[J]. BMJ,2024, 384:e076388. [34] Kobayashi T, Iwaki M, Nogami A, et al. Prediction of outcomes in patients with metabolic dysfunction-associated steatotic liver disease based on initial measurements and subsequent changes in magnetic resonance elastography[J]. J Gastroenterol,2024, 59(1): 56-65. [35] Paternostro R, Kwanten W J, Hofer B S, et al. Hepatic venous pressure gradient predicts risk of hepatic decompensation and liver-related mortality in patients with MASLD[J]. J Hepatol,2024, 81(5): 827-836. [36] Pennisi G, Di Maria G, Wong VW, et al. Impact of first and further decompensation in patients with compensated ACLD due to MASLD[J]. J Hepatol,2025, 83(6): 1266-1277. [37] Lam R, Jain D, Deng Y, et al. Advanced liver fibrosis predicts liver outcomes in biopsy-proven metabolic dysfunction-associated steatotic liver disease: A US-based single-center retrospective cohort study[J]. J Clin Transl Hepatol,2024, 12(12): 988-996. [38] Ni W, Shi J, Fan J G, et al. Guidelines for Diagnosis and Management of Metabolic Dysfunction-associated fatty liver disease in primary care (2025)[J]. J Clin Transl Hepatol,2026, 14(4): 487-498. [39] Yip T C, Lee H W, Lin H, et al. Prognostic performance of the two-step clinical care pathway in metabolic dysfunction-associated steatotic liver disease[J]. J Hepatol,2025, 83(2): 304-314. [40] Stefan N, Yki-Jarvinen H, Neuschwander-Tetri B A. Metabolic dysfunction-associated steatotic liver disease: heterogeneous pathomechanisms and effectiveness of metabolism-based treatment[J]. Lancet Diabetes Endocrinol,2025, 13(2): 134-148. [41] Younossi Z M, Zelber-Sagi S, Lazarus J V, et al. Global Consensus Recommendations for metabolic dysfunction-associated steatotic liver disease and steatohepatitis[J]. Gastroenterology,2025, 169(5): 1017-1032.e2. [42] Mcpherson S, Dyson J K, Jopson L, et al. How effective are experienced hepatologists at staging fibrosis using non-invasive fibrosis tests in patients with metabolic dysfunction-associated steatotic liver disease?[J]. Aliment Pharmacol Ther,2024, 60(2): 267-273. [43] Rigor J, Martins M E, Passos B, et al. Noninvasive tools for the assessment of fibrosis in metabolic dysfunction-associated steatotic liver disease[J]. Minerva Med,2024, 115(6): 660-670. [44] Ciardullo S, Cannistraci R, Muraca E, et al. Liver fibrosis, NT-ProBNP and mortality in patients with MASLD: a population-based cohort study[J]. Nutr Metab Cardiovasc Dis,2024, 34(4): 963-971. [45] Rinella M E, Neuschwander-Tetri B A, Siddiqui M S, et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease[J]. Hepatology,2023, 77(5): 1797-1835. [46] Friedman S L, Neuschwander-Tetri B A, Rinella M, et al. Mechanisms of NAFLD development and therapeutic strategies[J]. Nat Med,2018, 24(7): 908-922. [47] Loomba R, Friedman SL, Shulman GI. Mechanisms and disease consequences of nonalcoholic fatty liver disease[J]. Cell,2021, 184(10): 2537-2564. [48] Nishihara T, Miyoshi T, Nakashima M, et al. Prognostic value of metabolic dysfunction-associated steatotic liver disease over coronary computed tomography angiography findings: comparison with no-alcoholic fatty liver disease[J]. Cardiovasc Diabetol,2024, 23(1): 167. [49] De Filippo O, Di Pietro G, Nebiolo M, et al. Increased prevalence of high-risk coronary plaques in metabolic dysfunction associated steatotic liver disease patients: a meta-analysis[J]. Eur J Clin Invest,2024, 54(9): e14188. [50] Gurun M, Brennan P, Handjiev S, et al. Increased risk of chronic kidney disease and mortality in a cohort of people diagnosed with metabolic dysfunction associated steatotic liver disease with hepatic fibrosis[J]. PLoS One,2024, 19(4): e0299507. [51] Hsu C L, Schnabl B. The gut-liver axis and gut microbiota in health and liver disease[J]. Nat Rev Microbiol,2023, 21(11): 719-733. [52] Bataller R, Gines P, Nicolas J M, et al. Angiotensin Ⅱ induces contraction and proliferation of human hepatic stellate cells[J]. Gastroenterology,2000, 118(6): 1149-1156. [53] Bataller R, Schwabe R F, Choi Y H, et al. NADPH oxidase signal transduces angiotensin Ⅱ in hepatic stellate cells and is critical in hepatic fibrosis[J]. J Clin Invest,2003, 112(9): 1383-1394. [54] Yokohama S, Tokusashi Y, Nakamura K, et al. Inhibitory effect of angiotensin Ⅱ receptor antagonist on hepatic stellate cell activation in non-alcoholic steatohepatitis[J]. World J Gastroenterol,2006, 12(2): 322-326. [55] Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis[J]. Gastroenterology,2015, 149(2): 367-378.e5. [56] Newsome P N, Buchholtz K, Cusi K, et al. A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis[J]. N Engl J Med,2021, 384(12): 1113-1124. [57] Zinman B, Wanner C, Lachin J M, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes[J]. N Engl J Med,2015, 373(22): 2117-2128. [58] Harrison S A, Bedossa P, Guy C D, et al. A phase 3, randomized, controlled trial of Resmetirom in NASH with liver fibrosis[J]. N Engl J Med,2024, 390(6): 497-509. [59] Song Y, Ni W, Zheng M, et al. Vitamin E (300 mg) in the treatment of MASH: a multi-center, randomized, double-blind, placebo-controlled study[J]. Cell Rep Med,2025, 6(2): 101939. [60] Sterling R K, Lissen E, Clumeck N, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection[J]. Hepatology,2006, 43(6): 1317-1325. [61] Castera L, Friedrich-Rust M, Loomba R. Noninvasive assessment of liver disease in patients with nonalcoholic fattyliver disease[J]. Gastroenterology,2019, 156(5): 1264-1281.e4. [62] Sanyal A J, Newsome P N, Kliers I, et al. Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis[J]. N Engl J Med,2025, 392(21): 2089-2099. |
| No related articles found! |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||
